ATRIUM THERAPEUTICS INC (RNA) Stock Price & Overview
NASDAQ:RNA • US04965N1046
Current stock price
The current stock price of RNA is 14.54 USD. Today RNA is up by 3.71%. In the past month the price increased by 5.59%. In the past year, price decreased by -45.46%.
RNA Key Statistics
- Market Cap
- 248.779M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.00
- Dividend Yield
- N/A
RNA Stock Performance
RNA Stock Chart
RNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RNA. When comparing the yearly performance of all stocks, RNA is a bad performer in the overall market: 97.31% of all stocks are doing better.
RNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNA. RNA has a bad profitability rating. Also its financial health evaluation is rather negative.
RNA Earnings
RNA Forecast & Estimates
5 analysts have analysed RNA and the average price target is 25.5 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 14.54.
For the next year, analysts expect an EPS growth of 8.08% and a revenue growth -60.58% for RNA
RNA Groups
Sector & Classification
RNA Financial Highlights
Over the last trailing twelve months RNA reported a non-GAAP Earnings per Share(EPS) of -5. The EPS decreased by -80.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3861.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RNA Ownership
RNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.645B | ||
| AMGN | AMGEN INC | 15.25 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.68 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.84 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 11.2 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.55 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RNA
Company Profile
Atrium Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27.
Company Info
IPO: 2026-02-27
ATRIUM THERAPEUTICS INC
10578 Science Center Drive, Suite 125
San Diego CALIFORNIA 92037 US
CEO: Sarah Boyce
Employees: 47
Phone: 13026587581
ATRIUM THERAPEUTICS INC / RNA FAQ
Can you describe the business of ATRIUM THERAPEUTICS INC?
Atrium Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27.
What is the current price of RNA stock?
The current stock price of RNA is 14.54 USD. The price increased by 3.71% in the last trading session.
Does RNA stock pay dividends?
RNA does not pay a dividend.
What is the ChartMill rating of ATRIUM THERAPEUTICS INC stock?
RNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ATRIUM THERAPEUTICS INC (RNA) stock?
5 analysts have analysed RNA and the average price target is 25.5 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 14.54.
What is the expected growth for RNA stock?
The Revenue of ATRIUM THERAPEUTICS INC (RNA) is expected to decline by -60.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of RNA stock?
ATRIUM THERAPEUTICS INC (RNA) has a market capitalization of 248.78M USD. This makes RNA a Micro Cap stock.